Help protect
your patients
with APRETUDE

View head-to-head data

Starting patients on APRETUDE

HIV PROTECTION THEY DESERVE

PROVEN

Shield icon with upward arrow Shield icon with upward arrow

Efficacy and safety evaluated in two large-scale head-to-head clinical trials with the most diverse patient populations in HIV prevention trials to date1,2

POWERFUL

Shield icon with star Shield icon with star

Superior efficacy versus a daily
oral PrEP (TRUVADA)
demonstrated in two
clinical trials1,2*

  • >3X reduction in HIV-1 incidence in HPTN 083 (cisgender men
    and transgender women): HR
    0.31 (95% CI: 0.16 -0.58;
    P=0.0003
  • 12X reduction in HIV-1 incidence in HPTN 084 (cisgender
    women): HR 0.10 (95% CI: 0.04-0.27); P<0.0001

CONTINUOUS
PROTECTION

Shield icon with checkmark Shield icon with checkmark

Two months of continuous HIV protection with each injection
(after two initiation doses)§

*

HPTN 083 (N=4566) and HPTN 084 (N=3244) were randomized, double-blind, controlled trials evaluating the safety and efficacy of APRETUDE every 2 months vs daily oral TRUVADA for HIV-1 prevention in adults at risk of acquiring HIV-1. The primary endpoint of both studies was the rate of incident HIV-1 infections.

 

Incident HIV-1 infections: TDF/FTC: 39 in 3193 person-years (1.22/100 person-years) and APRETUDE: 12 in 3211 person-years (0.37/100 person-years).

 

Incident HIV-1 infections: TDF/FTC: 36 in 1946 person-years (1.85/100 person-years) and APRETUDE: 3 in 1960 person-years (0.15/100 person-years).

 

§Administered as an intramuscular injection by a healthcare professional every 2 months after 2 initiation injections administered 1 month apart. Adherence to the dosing schedule is strongly recommended. 
 

CI=confidence interval; HPTN=HIV Prevention Trials Network; HR=hazard ratio; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.

Headshot of bald Black man in his 30s, smiling, wearing a maroon blazer, on a green background

See which PrEP option patients chose in the open-label extension phase of the APRETUDE clinical trials.

See patient choice data

Photo portrait of three young people, on a purple background, featuring a Black man on the left, Black woman on the right, and a Latino man in the middle

Real people.
Real experiences.
Watch stories from
real people on APRETUDE.

Watch videos

Not actual patients.

Headshot of a White man with a beard in his 30s, looking straight ahead, on a green background

Information and resources to help your patients start APRETUDE.

Access and support

PMUS-CBTWCNT240012

References:

  1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women.
N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016

  2. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4